Brainstorm Cell Reconciled Depreciation Over Time
| BCLI Stock | USD 1.74 0.12 7.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Brainstorm Cell Performance and Brainstorm Cell Correlation. Brainstorm |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.45) | Return On Assets (1.78) | Return On Equity (11.22) |
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Reconciled Depreciation Analysis
Compare Brainstorm Cell Ther and related stocks such as Protalix Biotherapeutics, Corvus Pharmaceuticals, and Aldeyra Reconciled Depreciation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.7 M | 1.6 M | 1.3 M | 1.1 M | 1.1 M | 1.2 M | 1.1 M |
| CRVS | 842 K | 842 K | 842 K | 842 K | 842 K | 842 K | 842 K | 842 K | 847 K | 743 K | 632 K | 460 K | 367 K | 217 K | 206.2 K |
| ALDX | 37.8 K | 37.8 K | 37.8 K | 37.8 K | 37.8 K | 37.8 K | 37.8 K | 37.8 K | 71 K | 96.3 K | 56.2 K | 264.2 K | 258.7 K | 263 K | 164.6 K |
| HOWL | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 25 K | 150 K | 216 K | 1.1 M | 1.7 M | 1.8 M |
| EWTX | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 185 K | 272 K | 538 K | 1.7 M | 1.8 M |
| CELC | 104.7 K | 104.7 K | 104.7 K | 104.7 K | 104.7 K | 104.7 K | 104.7 K | 104.7 K | 223 K | 339 K | 385.6 K | 303.2 K | 210.9 K | 163.8 K | 271.9 K |
| CCCC | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.6 M | 1.6 M | 1.5 M | 1.7 M | 2 M | 1.8 M |
| TRVI | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 23 K | 39 K | 47 K | 50 K | 43 K | 103 K | 108.2 K |
| CUE | 419.6 K | 419.6 K | 419.6 K | 419.6 K | 419.6 K | 419.6 K | 419.6 K | 419.6 K | 760 K | 5.2 M | 1.1 M | (1.8 M) | 1.8 M | 3.4 M | 3.6 M |
| BCAB | 794 K | 794 K | 794 K | 794 K | 794 K | 794 K | 794 K | 794 K | 794 K | 860 K | 1 M | 1.3 M | 1.2 M | 1.2 M | 1.2 M |
| PASG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 134 K | 800 K | 1.5 M | 3.7 M | 3.9 M | 4.1 M |
| HCWB | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 421.8 K | 595.9 K | 543.6 K | 717.9 K | 1.1 M | 748.2 K |
| GBIO | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 347 K | 1.9 M | 3.4 M | 4.5 M | 5.1 M | 5.3 M | 3.8 M |
| CNTB | 790 K | 790 K | 790 K | 790 K | 790 K | 790 K | 790 K | 790 K | 790 K | 790 K | 1.4 M | 4.1 M | 6.9 M | 988 K | 938.6 K |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 155 K | 199 K | 531 K | 383 K | 279 K |
| TERN | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 195 K | 394 K | 512 K | 1 M | 881 K | 564.5 K |
| XFOR | 195 K | 195 K | 195 K | 195 K | 195 K | 195 K | 195 K | 195 K | 155 K | 103 K | 351 K | 499 K | 513 K | 481 K | 361 K |
| INZY | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 26 K | 83 K | 217 K | 674 K | 744 K | 822 K | 470.4 K |
| MREO | 36.1 K | 36.1 K | 36.1 K | 36.1 K | 36.1 K | 36.1 K | 36.1 K | 36.1 K | 37.8 K | 1.6 M | 1.6 M | 642 K | 727 K | 1.1 M | 892.6 K |
Brainstorm Cell Ther and related stocks such as Protalix Biotherapeutics, Corvus Pharmaceuticals, and Aldeyra Reconciled Depreciation description
My Equities
My Current Equities and Potential Positions
| Brainstorm Cell Therapeutics | BCLI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.74
Check out Brainstorm Cell Performance and Brainstorm Cell Correlation. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Brainstorm Cell technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.